Perspective Therapeutics, Inc. CATX
Perspective Therapeutics, Inc. (NYSE: CATX) is an oncology drug developer. Its lead program, VMT-alpha-NET, is in Phase 1 for Neuroendocrine tumors (Pb-212 alpha therapy). Its next catalyst on record is VMT-alpha-NET: ESMO data update (October 2026).
Upcoming catalysts
- October 2026VMT-alpha-NET — ESMO data update
ESMO update 2026-10-23
Next further out: VMT-alpha-NET — Phase 3 site activation (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VMT-alpha-NET | NETs | radiopharmaceutical | Phase 1 |
| VMT01 | Melanoma | radiopharmaceutical | Phase 1 |
| PSV359 | FAP-alpha solid tumors | radiopharmaceutical | Phase 1 |
| PSV594 | Undisclosed | radiopharmaceutical | Pre-clinical |
Recent results and decisions
- Oct 23, 2026positive VMT-α-NET demonstrates ORR of 33% in Cohort 2 (5.0 mCi) and 50% in Cohort 3 (6.0 mCi) with 72% PFS at 18 months and no dose-limiting toxicities in Phase 1/2a trial.
ORR, including unconfirmed responses, was 33% in Cohort 2 (5.0 mCi, n=46) and 50% in Cohort 3 (6.0 mCi, n=20, as of September 10, 2026).
Filing - Oct 8, 2026n/a FDA granted Fast Track Designation to PSV359 for FAP-positive solitary fibrous tumors (designation, not an approval).
Programs that receive Fast Track Designation may benefit from more frequent interactions with the FDA regarding the development program.
Filing - Oct 8, 2026n/a FDA grants Fast Track Designation for [212Pb]PSV359 in adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors.
The FDA's Fast Track program is intended to facilitate development and expedite the review of therapies for serious conditions with unmet medical needs.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.